Provided by Tiger Trade Technology Pte. Ltd.

Takeda Pharmaceutical Co Ltd

19.05
+0.41002.20%
Pre-market: 19.050.00000.00%04:00 EDT
Volume:2.71M
Turnover:51.62M
Market Cap:60.63B
PE:-59.83
High:19.10
Open:19.02
Low:19.00
Close:18.64
52wk High:19.10
52wk Low:12.99
Shares:3.18B
Float Shares:3.09B
Volume Ratio:1.14
T/O Rate:0.09%
Dividend:0.63
Dividend Rate:3.33%
EPS(TTM):-0.3184
EPS(LYR):-0.3042
ROE:-2.26%
ROA:2.69%
PB:1.27
PE(LYR):-62.61

Loading ...

Jury finds Takeda caused about $885M in damages over generic delay, Reuters says

TIPRANKS
·
May 19

Jury Orders Takeda to Pay Hundreds of Millions in Antitrust Case, Bloomberg Reports

MT Newswires Live
·
May 19

Takeda told to pay hundreds of millions for generic drug delay, Bloomberg says

TIPRANKS
·
May 19

Takeda ordered by pay hundreds of millions in antitrust case, Bloomberg says

TIPRANKS
·
May 19

Justice Department announces $13.67M civil settlement with Takeda

TIPRANKS
·
May 15

Takeda Pharmaceutical Settles DOJ's Kickback Case for $13.7 Million

Dow Jones
·
May 15

Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring

Reuters
·
May 14

Takeda's Next Wave Of Drugs Has Investors Watching Closely

Benzinga Earnings
·
May 13

Takeda Pharmaceutical Q4 Adj. EPS $0.28 Beats $0.21 Estimate, Sales $6.978B Miss $7.050B Estimate

Benzinga Earnings
·
May 13

Takeda Pharmaceutical Fiscal Q4 Core Earnings, Revenue Rise; Issues Fiscal 2026 Outlook

MT Newswires Live
·
May 13

Press Release: Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

Dow Jones
·
May 13

Takeda Pharmaceutical Co Ltd expected to post earnings of JPY117.96 a share - Earnings Preview

Reuters
·
May 11

Immigration Uncovers Trading Scam in Batam, 210 Foreigners Nabbed

Tempo
·
May 09

Takeda Advances TAK-279 Into Phase 2a Crohn’s Study, Signaling Long-Term GI Growth Ambitions

TIPRANKS
·
May 08

Takeda Advances Pediatric ENTYVIO Study, Supporting Long-Term Growth Potential

TIPRANKS
·
May 08

Earning Preview: Takeda Pharmaceutical Co Ltd revenue is expected to increase by 6.75% this quarter, and institutional views are constructive

Earnings Agent
·
May 06

Takeda Says Phase 2/3 Trial of TAK-881 Meets Endpoint in Primary Immunodeficiency Disease

MT Newswires Live
·
May 04

Protagonist Therapeutics Opts Out of Rusfertide US Profit-Sharing Arrangement With Takeda Pharmaceutical

MT Newswires Live
·
Apr 28

Takeda Targets Older Adults With New Dengue Vaccine Study, Eyeing Long-Term Market Upside

TIPRANKS
·
Apr 24

Takeda’s TAK-505 Trial Marks a New Bet on Difficult Solid Tumors

TIPRANKS
·
Apr 24